83410-37-1

Basic information

• Product Name: 2,6-DIMETHYL-5-IODO-4(3H)-PYRIMIDONE
• Synonyms: 2,6-DIMETHYL-5-IODO-4(3H)-PYRIMIDONE;5-iodo-2,6-dimethyl-4-pyrimidinol(SALTDATA: FREE);5-Iodo-2,6-diMethyl-1H-pyriMidin-4-one;5-iodo-2,6-dimethyl-4(3H)-Pyrimidinone
• CAS NO: 83410-37-1
• Molecular Formula: C₆H₇IN₂O
• Molecular Weight: 250.04
• Mol File: 83410-37-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 254.9 °C at 760 mmHg
• Flash Point: 107.9 °C
• Appearance: /
• Density: 2.03 g/cm³
• Vapor Pressure: 0.0168mmHg at 25°C
• Refractive Index: 1.687
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 2,6-DIMETHYL-5-IODO-4(3H)-PYRIMIDONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-DIMETHYL-5-IODO-4(3H)-PYRIMIDONE(83410-37-1)
• EPA Substance Registry System: 2,6-DIMETHYL-5-IODO-4(3H)-PYRIMIDONE(83410-37-1)

Safety Data

• Hazardous Substances Data: 83410-37-1(Hazardous Substances Data)

Usage

General Description

2,6-DIMETHYL-5-IODO-4(3H)-PYRIMIDONE is a chemical compound with the molecular formula C6H7IN2O. It is a pyrimidone derivative that contains two methyl groups and an iodine atom attached to the pyrimidone ring. 2,6-DIMETHYL-5-IODO-4(3H)-PYRIMIDONE has been studied for its potential pharmaceutical applications, particularly in the field of medicinal chemistry. Its unique structure and properties make it a promising candidate for further research and development in the synthesis of new pharmaceuticals with potentially beneficial biological activities. Additionally, its iodine substituent may also make it useful for certain chemical reactions and transformations in organic synthesis. Overall, 2,6-DIMETHYL-5-IODO-4(3H)-PYRIMIDONE is a valuable chemical compound with potential applications in both the pharmaceutical and chemical industries.

InChI:InChI=1/C6H7IN2O/c1-3-5(7)6(10)9-4(2)8-3/h1-2H3,(H,8,9,10)

Upstream product

• 6622-92-0 2,6-dimethyl-1H-pyrimidin-4-one 
• 6622-92-0 4-hydroxy 2,6-dimethylpyrimidine 

Downstream Products

• 929880-37-5 2,6-dimethyl-5-(2-p-tolylethynyl)pyrimidin-4-ol 
• 1369769-18-5 (1R,2S)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)-2-({[1-(methoxymethyl)-2,4-dimethyl-6-oxo-1,6-dihydropyrimidin-5-yl]oxy}methyl)cyclopropanecarboxamide 
• 1369769-14-1 5-{[(1S,2R)-1-(3-fluorophenyl)-2-(hydroxymethyl)cyclopropyl]methoxy}-3-(methoxymethyl)-2,6-dimethylpyrimidin-4(3H)-one 
• 1369769-16-3 (1R,2S)-2-(3-fluorophenyl)-2-({[1-(methoxymethyl)-2,4-dimethyl-6-oxo-1,6-dihydropyrimidin-5-yl]oxy}methyl)cyclopropanecarboxylic acid 
• 1369769-15-2 (1R,2S)-2-(3-fluorophenyl)-2-({[1-(methoxymethyl)-2,4-dimethyl-6-oxo-1,6-dihydropyrimidin-5-yl]oxy}methyl)cyclopropanecarbaldehyde 
• 1369769-13-0 [(1R,2S)-2-(3-fluorophenyl)-2-({[1-(methoxymethyl)-2,4-dimethyl-6-oxo-1,6-dihydropyrimidin-5-yl]oxy}methyl)cyclopropyl]methyl acetate 
• 1369769-11-8 5-(benzyloxy)-3-(methoxymethyl)-2,6-dimethylpyrimidin-4(3H)-one 
• 1369766-54-0 (1R,2S)-2-{[(2,4-dimethyl-6-oxo-1,6-dihydropyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide 
• 1228362-39-7 4-amino-2,6-dimethyl-5-{[4-(trifluoromethyl)phenyl]ethynyl}pyrimidine 
• 1228362-38-6 4-chloro-2,6-dimethyl-5-{[4-(trifluoromethyl)phenyl]ethynyl}pyrimidine 
• 1027898-62-9 1-(4-{[2'-(2-tert-Butyl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-2,6-dimethyl-pyrimidin-5-yl)-ethanone 
• 159237-77-1 4-(4-bromobenzylamino)-2,6-dimethyl-5-(1-ethoxyvinyl)pyrimidine 
• 159237-74-8 methyl(4-(4-bromobenzylamino)-2,6-dimethylpyrimidin-5-yl)ketone 

Relevant articles and documents

Compounds for treating spinal muscular atrophy

Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.

Synthesis of novel 5,6-substituted furo[2,3-d]pyrimidines via Pd-catalyzed cyclization of alkynylpyrimidinols with aryl iodides

A flexible method for the synthesis of 5,6-disubstituted furo[2,3-d]pyrimidine derivatives is described. The key step is a palladium-catalyzed arylative cyclization of alkynylpyrimidinols with various aryl iodides, which gave the title compounds in 36-75% yield.

Substituted pyridopyrimidines and antihypertensives

This invention relates to substituted pyridopyrimidinones of general formula (I): STR1 wherein R1 and R2 are independently H, lower alkyl containing 1 to 6 carbon atoms, hydroxyalkyl containing 1 to 6 carbon atoms, formyl, carbonylalkyl containing 1 to 6 carbon atoms, carboxy, or carboxyalkyl containing 1 to 6 carbon atoms; R3 and R4 are independently H, lower alkyl containing 1 to 6 carbon atoms, hydroxy; R3a and R4a are H, and when taken together with R3 and R4 respectively comprise a carbonyl; with the proviso that at least one of the groups R1 and R2 must be hydroxyalkyl, formyl, carbonylalkyl containing 1 to 6 carbon atoms, carboxy, or carboxyalkyl containing 1 to 6 carbon atoms; or R3 and R4 must be hydroxy or taken together with R3a and R4a respectively must comprise a carbonyl; n is 0 to 3; Ar1 is STR2 wherein W is H, lower alkyl containing 1 to 6 carbon atoms, halogen, hydroxy, or lower alkoxy containing 1 to 6 carbon atoms; Ar2 is STR3 wherein X is CO2 H, CN, or STR4 wherein R5 is H, CH3, tert-butyl, tri-n-butylstannyl, or triphenylmethyl; and the pharmaceutically acceptable salts thereofuseful for treating hypertension and congestive heart failure, to pharmaceutical compositions, and to methods for production thereof.